Burning Rock Biotech (NASDAQ:BNR) Stock Price Up 36% - What's Next?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) rose 36% during trading on Monday . The company traded as high as $10.74 and last traded at $10.17. Approximately 312,101 shares traded hands during mid-day trading, an increase of 447% from the average daily volume of 57,097 shares. The stock had previously closed at $7.48.

Burning Rock Biotech Stock Performance

The stock's 50 day simple moving average is $4.99 and its 200 day simple moving average is $4.56. The firm has a market capitalization of $109.43 million, a P/E ratio of -5.38 and a beta of 0.83.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last released its quarterly earnings data on Friday, June 6th. The company reported ($0.17) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative net margin of 45.41% and a negative return on equity of 38.33%. The business had revenue of $18.34 million for the quarter.

Hedge Funds Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Citadel Advisors LLC acquired a new stake in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 12,267 shares of the company's stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.12% of Burning Rock Biotech as of its most recent filing with the Securities & Exchange Commission. 30.03% of the stock is currently owned by institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.